Moderna’s stock price has taken a beating over the past six months, shedding 33.6% of its value and falling to $26.85 per ...

Moderna Inc. (NASDAQ:MRNA) is one of the best mid cap growth stocks to invest in now. On June 12, the US FDA expanded the ...

First, let's back up a bit and take a look at the Moderna story, from the glory days of a few years ago to its troubles today ...

The Food and Drug Administration department of the US has updated its warning about rare heart risk associated with to ...

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...

The Department of Health and Human Services has defended cuts to vaccine research with statements that mislead on the safety ...

Moderna Inc. (NASDAQ:MRNA) is one of the best mid cap growth stocks to invest in now. On June 12, the US FDA expanded the approval for Moderna’s respiratory syncytial virus/RSV vaccine, mRESVIA ...

Moderna (MRNA) ended the recent trading session at $25.90, demonstrating a +1.97% change from the preceding day's closing price. This change outpaced the S&P 500's 0.22% loss on the day. Elsewhere ...

Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's ...

The FDA approved mResvia for the prevention of RSV in people ages 18 to 59 years who are at increased risk for severe disease ...